The trajectory of Viagra presents a nuanced case for stakeholders in the medicinal sector. While initially a blockbuster success, producing vast sums, the intellectual property end and the subsequent entry of cheaper alternatives have considerably changed revenue. This presents questions about the long-term viability of analogous therapeutic projec